•Identified
a novel kinase whose inhibition prevents NLRP3 inflammasome
activation by all its known stimuli, and identified its essential catalytic
pocket and mechanism of action
•Applying
for a patent application (US Provisional Application Serial no. 62/690,175)
covering the use of IRF1 and/or CMPK2
genetic/chemical inhibitors to treat NLRP3 inflammasome-associated
diseases in the process
•Business
model: collaboration to identify small molecule inhibitors of this kinase would
be of interest as well as licensing the technology